A pretransplant ‘Booster’ Dose of an Anti-t-Activated RATG (anti-jurkat) Induces massive endogenous IL-10 release with Transient Drastic Lymphocyte Depletion at the Priming Time of Antigen Presentation with 100% of Patients and Graft Survival at a Mean of 30 Months in 17 Kidney Retransplantations.